EWSR1 Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q01844 |
---|---|
Clone Names | 100507199 |
Gene ID | 2130 |
---|---|
Other Names | RNA-binding protein EWS, EWS oncogene, Ewing sarcoma breakpoint region 1 protein, EWSR1, EWS |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | EWSR1 |
---|---|
Synonyms | EWS |
Function | Might normally function as a transcriptional repressor. EWS- fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. |
Cellular Location | Nucleus. Cytoplasm. Cell membrane. Note=Relocates from cytoplasm to ribosomes upon PTK2B/FAK2 activation |
Tissue Location | Ubiquitous. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a multifunctional protein that isinvolved in various cellular processes, including gene expression,cell signaling, and RNA processing and transport. The proteinincludes an N-terminal transcriptional activation domain and aC-terminal RNA-binding domain. Chromosomal translocations betweenthis gene and various genes encoding transcription factors resultin the production of chimeric proteins that are involved intumorigenesis. These chimeric proteins usually consist of theN-terminal transcriptional activation domain of this protein fusedto the C-terminal DNA-binding domain of the transcription factorprotein. Mutations in this gene, specifically a t(11;22)(q24;q12)translocation, are known to cause Ewing sarcoma as well asneuroectodermal and various other tumors. Alternative splicing ofthis gene results in multiple transcript variants. Relatedpseudogenes have been identified on chromosomes 1 and 14. [providedby RefSeq].
References
Lagirand-Cantaloube, J., et al. Biochem. Biophys. Res. Commun. 399(4):705-710(2010)Kumagai, A., et al. Am. J. Clin. Pathol. 134(2):323-331(2010)Aryee, D.N., et al. Cancer Res. 70(10):4015-4023(2010)Riggi, N., et al. Genes Dev. 24(9):916-932(2010)Olsen, J.V., et al. Cell 127(3):635-648(2006)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.